300 results on '"Giugliano, Robert P"'
Search Results
2. Emergent Coronary Thrombectomy for Acute Myocardial Infarction Immediately Following Craniotomy with Tumor Resection
3. Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation: Analysis From COMBINE-AF
4. Chronic cardiovascular–kidney disorder: a new conceptual framework
5. Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI
6. Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial
7. Author Correction: Chronic cardiovascular–kidney disorder: a new conceptual framework
8. Efficacy and Safety of Non–Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation
9. Benefit of Combination Ezetimibe/Simvastatin Among High-Risk Populations: Lessons from the IMPROVE-IT Trial
10. Switching to Direct Anticoagulation or Continued Vitamin-K Antagonists in Frail Patients With Atrial Fibrillation in Whom Vitamin-K Antagonists Are Tolerated?
11. Neutrophil-lymphocyte ratio and clinical outcomes in 19,697 patients with atrial fibrillation: Analyses from ENGAGE AF- TIMI 48 trial
12. Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review
13. Abstract 14566: Long-Term Efficacy of Evolocumab in Patients With and Without Multivessel Coronary Artery Disease
14. Abstract 12946: Among Patients With Acute Coronary Syndromes, is the Risk of Hyperglycemia for In-Hospital Mortality Similar in Men and Women?
15. Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus
16. Risks of Heart Failure, Stroke, and Bleeding in Atrial Fibrillation According to Heart Failure Phenotypes
17. Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association
18. The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis
19. The non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with high-normal renal function – A systematic review
20. Biomarker Prediction of Complex Coronary Revascularization Procedures in the FOURIER Trial
21. Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF
22. Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction
23. Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups
24. Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction
25. Acute coronary syndromes
26. Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient-Level Meta-Analysis From COMBINE AF.
27. Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial.
28. Novel Polygenic Risk Score and Established Clinical Risk Factors for Risk Estimation of Aortic Stenosis
29. Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations
30. Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease
31. Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT
32. Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT
33. Abstract 12361: Efficacy and Safety of NOACs vs. Warfarin Across the Continuous Range of Body Mass Index and Body Weight: Insights From COMBINE-AF
34. Application of the Win Ratio Method in the ENGAGE AF-TIMI 48 Trial Comparing Edoxaban With Warfarin in Patients With Atrial Fibrillation.
35. Cardiovascular Benefit of Lowering LDL Cholesterol Below 40 mg/dl
36. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex
37. From Cardiorenal Syndrome to Chronic Cardiovascular and Kidney Disorder
38. Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG
39. Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL
40. Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events
41. Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition
42. Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation
43. Impact of Ezetimibe on New‐Onset Diabetes: A Substudy of IMPROVE‐IT
44. Serial assessment of biomarkers and heart failure outcomes in patients with atrial fibrillation
45. Response by O’Donoghue et al to Letter Regarding Article, “Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease”
46. REDUCTION IN TOTAL CARDIOVASCULAR EVENTS WITH THE PCSK9 INHIBITOR EVOLOCUMAB IN PATIENTS WITH CARDIOVASCULAR DISEASE IN THE COMBINED FOURIER AND FOURIER OPEN-LABEL EXTENSION (OLE) STUDIES
47. GENETICALLY MEDIATED VASCULAR ENDOTHELIAL CELL DYSFUNCTION AND ITS DEPENDENCE ON SERUM LDL CHOLESTEROL LEVELS FOR THE DEVELOPMENT OF CORONARY ARTERY ATHEROSCLEROSIS: GENETIC INSIGHTS FROM THE UKBB AND FOURIER TRIAL
48. EDOXABAN 30 MG VS WARFARIN IN 2,406 PATIENTS AGE ≥80 YEARS: A RANDOMIZED ANALYSIS FROM ENGAGE AF-TIMI 48
49. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE
50. Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.